Patient-reported functional outcome measures and treatment choice for prostate cancer

BMC Urology

Table 3 Proportions of men who reported ‘moderate-to-big bothers’ by treatment type, SA-PCCOC registry (2010–2019)

Bother type	Rx	Baseline bother^#		12 months bother^##
Bother type		%	95% CI	%	95% CI
Sexual bother	RP	22.0	19.3, 24.7	42.8	38.9, 46.8
Sexual bother	EBRT	22.6	16.9, 28.4	28.8	16.8, 40.8
	BT	20.0	10.8, 29.1	31.3	16.6, 45.9
	AS	19.8	14.4, 25.2	37.0	26.1, 47.8
Urinary bother	RP	9.7	7.9, 11.5	9.0	6.8, 11.2
Urinary bother	EBRT	13.6	9.6, 17.5	5.9	2.0, 9.9
	BT	11.6	5.1, 18.1	10.8	1.3, 20.3
	AS	12.1	7.3, 16.8	7.4	0.4, 14.3
Bowel bother^¥	RP	3.5	2.4, 4.7	5.6	3.9, 7.3
Bowel bother^¥	EBRT	6.1	3.1, 9.0	8.2	3.2, 13.2
	BT	4.5	0.6, 8.5	0	-
	AS	5.4	1.1, 9.7	10.4	2.0, 18.8

Rx, treatment type; RP, radical prostatectomy; EBRT, external beam radiation therapy; BT, brachytherapy; AS, active surveillance; CI, confidence interval
^#Adjusted for age, SEIFA score, PSA level, risk category and primary symptoms
^##Adjusted for baseline bother of the respective function, age, SEIFA score, PSA level, risk category and primary symptoms
Proportions were predicted from binary logistic regression models (moderate/big bother = 1 vs. no/very small/small bother = 0)

ISSN: 1471-2490